Physician profile
Miklos Simon
NPI 1710919972
$12,690.26
in general payments reported to CMS, 2019-2025
10 companies · $3,017 in 2025
The $3,017 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,397 · 2020: $992 · 2021: $1,625 · 2023: $3,545 · 2024: $114 · 2025: $3,017.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,818 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,590 · Food and Beverage: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,818.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,589.98 |
| Food and Beverage | $268.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,277.20 | 2019-2020 | |
| Incyte Corporation | $3,528.02 | 2023 | |
| Avyxa Pharma, LLC | $3,016.93 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,613.50 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $111.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.57 | 2024 | Fruzaqla |
| Seagen INC. | $17.33 | 2023 | Adcetris |
| Astellas Pharma US INC | $13.50 | 2024 | Xospata |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miklos Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.